{
    "clinical_study": {
        "@rank": "63913", 
        "biospec_descr": {
            "textblock": "miRNA in platelet(Platelet Rich Plasma)"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we\n      will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the\n      basis of medical criteria (clinical guidelines) routine as aspirin + clopidogrel or aspirin\n      + ticagrelor, according to medical guidelines currently no other disposal alternative\n      proposal (unless adverse drug tolerance or bleeding can not be administered); idea of \u200b\u200bthis\n      experiment for acute coronary syndrome or conventional cardiac catheterization after\n      stenting, platelet miRNA expression (miR-96 , miR-200b, miR-495, miR-107) after cardiac\n      catheterization and interventional treatment of clopidogrel or ticagrelor acceptance of\n      platelet reactivity (PRU) correlation values \u200b\u200b(given clopidogrel or ticagrelor determined\n      by the clinician, the patient follow-up experiment to track only and observation), aims to\n      explore under different platelet reactivity (hyper-reactive or hypo-reactive), their\n      differences in miRNA performance."
        }, 
        "brief_title": "The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "PRU", 
            "miRNA"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1 under DAPT (dual antiplatelet therapy) of stable angina patients for elective stent\n        implantation.\n\n        2. DAPT 24 hours after treatment PRU (platelet activity units) values. (Drug unresponsive\n        patients was defined as PRU> 235).\n\n        Exclusion Criteria:\n\n        1.Not suitable for the treatment of patients with DAPT. (Active peptic ulceration or\n        bleeding) 2 patients of aspirin, clopidogrel, ticagrelor, cilostazol medication\n        intolerance.\n\n        3 contraindications for aspirin, clopidogrel, ticagrelor, cilostazol drug usage (such as\n        heart failure patients not suitable for use cilostazol)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "stable angina who received routine dual antiplatelet agents therapy."
            }
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101437", 
            "org_study_id": "TCHIRB-I021003"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "chenyuehchung.tw@yahoo.com.tw", 
                "last_name": "Chen Yueh Chung, chief doctor", 
                "phone": "886227093600", 
                "phone_ext": "3741"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan"
                }, 
                "name": "Taipei city hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "chenyuehchung.tw@yahoo.com.tw", 
            "last_name": "Chen Yueh Chung, chief doctor", 
            "phone": "886227093600", 
            "phone_ext": "3741"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Ministry of Health and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MACE", 
            "safety_issue": "Yes", 
            "time_frame": "6 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101437"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Taipei City Hospital", 
            "investigator_full_name": "Yueh-Chung, Chen", 
            "investigator_title": "chief of ICU", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Taipei City Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taipei City Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}